Glucagon‑Like Peptide‑1 Receptor Agonists Lawsuits

A large and rapidly growing wave of lawsuits targets the class of medications known as GLP-1 receptor agonists (often called GLP-1 drugs). These drugs—such as Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro—are prescribed for type 2 diabetes and obesity/weight-management. The litigation (MDL No. 3094) has consolidated many of these claims in the Eastern District of Pennsylvania. Learn more about glucagon‑like peptide‑1 receptor agonists lawsuits by connecting with our team of mass torts attorneys.

What the Lawsuits Allege

• Plaintiffs claim these drugs caused serious injuries such as gastroparesis (delayed stomach emptying), non-arteritic anterior ischemic optic neuropathy (NAION – a form of vision loss), and other gastrointestinal or eye disorders.

• Allegations include: failure to warn patients and physicians of risks, defective design or insufficient safety testing, misleading marketing, and negligent monitoring of adverse effects.

• The MDL court has required plaintiffs alleging gastroparesis to provide objective diagnostic testing as a threshold for proceeding.

Why This Matters

The number of claims is increasing quickly: as of November 2025, over 2,900 lawsuits were reported pending in the national GLP-1 litigation. These drugs are widely used—both by diabetes patients and increasingly for weight-loss—creating broader exposure for manufacturers. Additionally, the litigation may drive company settlements, label changes, increased regulatory scrutiny, and impact how emerging drugs are marketed and monitored.

Who May Have a Claim

Individuals who:

• Took a GLP-1 drug and subsequently developed gastroparesis, serious vision loss, or other qualifying injuries

• Have medical records linking the drug use with the onset of the injury

• Can demonstrate causation, i.e., that the manufacturer should have warned of the risk

Connect with Phillips Law Group to learn more about your options for taking legal action.

How We Can Help

At Phillips Law Group, we focus on complex pharmaceutical product-liability claims. We will:

• Review your drug usage history, medical records, and injury timeline

• Determine eligibility under the GLP-1 litigation track

• Coordinate with medical and scientific experts to build causation evidence

• Pursue compensation for medical costs, lost income, pain and suffering

We also work on contingency basis – meaning no fees unless we win.

Contact Our Team to Learn More About GLP-1 Lawsuits

If you or a loved one was injured after using a GLP-1 drug, call Phillips Law Group at 602-222-2222 for a free and confidential consultation to learn more about glucagon‑like peptide‑1 receptor agonists lawsuits.